Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2011 | Research

Differential hRad17 expression by histologic subtype of ovarian cancer

Authors: Jennifer L Young, E Colin Koon, Joseph Kwong, William R Welch, Michael G Muto, Ross S Berkowitz, Samuel C Mok

Published in: Journal of Ovarian Research | Issue 1/2011

Abstract

Background

In the search for unique ovarian cancer biomarkers, ovarian specific cDNA microarray analysis identified hRad17, a cell cycle checkpoint protein, as over-expressed in ovarian cancer. The aim of this study was to validate this expression.

Methods

Immunohistochemistry was performed on 72 serous, 19 endometrioid, 10 clear cell, and 6 mucinous ovarian cancers, 9 benign ovarian tumors, and 6 normal ovarian tissue sections using an anti-hRad17 antibody. Western blot analysis and quantitative PCR were performed using cell lysates and total RNA prepared from 17 ovarian cancer cell lines and 6 normal ovarian epithelial cell cultures (HOSE).

Results

Antibody staining confirmed upregulation of hRad17 in 49.5% of ovarian cancer cases. Immunohistochemistry demonstrated that only 42% of serous and 47% of endometrioid subtypes showed overexpression compared to 80% of clear cell and 100% of mucinous cancers. Western blot confirmed overexpression of hRad17 in cancer cell lines compared to HOSE. Quantitative PCR demonstrated an upregulation of hRad17 RNA by 1.5-7 fold. hRad17 RNA expression differed by subtype.

Conclusions

hRad17 is over-expressed in ovarian cancer. This over-expression varies by subtype suggesting a role in the pathogenesis of these types. Functional studies are needed to determine the potential role of this protein in ovarian cancer.

Available only for authorised users

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006, 56: 106–130. 10.3322/canjclin.56.2.106PubMedCrossRef

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005, 99: 267–277. 10.1016/j.ygyno.2005.06.040PubMedCrossRef

Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim J-H, Cramer DW, Berkowitz RS, Mok SC: Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004, 10: 3474–3478. 10.1158/1078-0432.CCR-03-0365PubMedCrossRef

Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001, 93: 1458–1464. 10.1093/jnci/93.19.1458PubMedCrossRef

Bandera CA, Ye B, Mok SC: New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003, 15: 51–55. 10.1097/00001703-200302000-00008PubMedCrossRef

Wong KK, Cheng RS, Mok SC: Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001, 30: 670–675.PubMed

Bao S, Chang MS, Auclair D, Sun Y, Wang Y, Wong WK, Zhang J, Liu Y, Qian X, Sutherland R, et al.: HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res 1999, 59: 2023–2028.PubMed

Parker AE, Van de Weyer I, Laus MC, Verhasselt P, Luyten WH: Identification of a human homologue of the Schizosaccharomyces pombe rad17+ checkpoint gene.[erratum appears in J Biol Chem 1999 Aug 20;274(34):24438]. J Biol Chem 1998, 273: 18340–18346. 10.1074/jbc.273.29.18340PubMedCrossRef

Li L, Peterson CA, Kanter-Smoler G, Wei YF, Ramagli LS, Sunnerhagen P, Siciliano MJ, Legerski RJ: hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation. Oncogene 1999, 18: 1689–1699. 10.1038/sj.onc.1202469PubMedCrossRef

10.

Post SM, Tomkinson AE, Lee EYHP: The human checkpoint Rad protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase epsilon. Nucleic Acids Res 2003, 31: 5568–5575. 10.1093/nar/gkg765PubMedCentralPubMedCrossRef

11.

Chang MS, Sasaki H, Campbell MS, Kraeft SK, Sutherland R, Yang CY, Liu Y, Auclair D, Hao L, Sonoda H, et al.: HRad17 colocalizes with NHP2L1 in the nucleolus and redistributes after UV irradiation. J Biol Chem 1999, 274: 36544–36549. 10.1074/jbc.274.51.36544PubMedCrossRef

12.

Bao S, Tibbetts RS, Brumbaugh KM, Fang Y, Richardson DA, Ali A, Chen SM, Abraham RT, Wang XF: ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. Nature 2001, 411: 969–974. 10.1038/35082110PubMedCrossRef

13.

Nabetani A, Yokoyama O, Ishikawa F: Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. J Biol Chem 2004, 279: 25849–25857. 10.1074/jbc.M312652200PubMedCrossRef

14.

Wang X, Wang L, Callister MD, Putnam JB, Mao L, Li L: Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. Cancer Res 2001, 61: 7417–7421.PubMed

15.

Post S, Weng YC, Cimprich K, Chen LB, Xu Y, Lee EY: Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G(1)/S checkpoint activation in response to DNA damage. Proc Natl Acad Sci USA 2001, 98: 13102–13107. 10.1073/pnas.231364598PubMedCentralPubMedCrossRef

16.

Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J, Sancar A: Loading of the human 9–1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc Natl Acad Sci USA 2003, 100: 1633–1638. 10.1073/pnas.0437927100PubMedCentralPubMedCrossRef

17.

Rauen M, Burtelow MA, Dufault VM, Karnitz LM: The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9. J Biol Chem 2000, 275: 29767–29771. 10.1074/jbc.M005782200PubMedCrossRef

18.

Griffith JD, Lindsey-Boltz LA, Sancar A: Structures of the human Rad17-replication factor C and checkpoint Rad 9–1-1 complexes visualized by glycerol spray/low voltage microscopy. J Biol Chem 2002, 277: 15233–15236. 10.1074/jbc.C200129200PubMedCrossRef

19.

Lindsey-Boltz LA, Bermudez VP, Hurwitz J, Sancar A: Purification and characterization of human DNA damage checkpoint Rad complexes. Proc Natl Acad Sci USA 2001, 98: 11236–11241. 10.1073/pnas.201373498PubMedCentralPubMedCrossRef

20.

Song W, Levin DS, Varkey J, Post S, Bermudez VP, Hurwitz J, Tomkinson AE: A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes. J Biol Chem 2007, 282: 22721–22730. 10.1074/jbc.M703774200PubMedCrossRef

21.

Bao S, Lu T, Wang X, Zheng H, Wang L-E, Wei Q, Hittelman WN, Li L: Disruption of the Rad9/Rad1/Hus1 (9–1-1) complex leads to checkpoint signaling and replication defects. Oncogene 2004, 23: 5586–5593. 10.1038/sj.onc.1207753PubMedCrossRef

22.

Tsao C-C, Geisen C, Abraham RT: Interaction between human MCM7 and Rad17 proteins is required for replication checkpoint signaling. Embo J 2004, 23: 4660–4669. 10.1038/sj.emboj.7600463PubMedCentralPubMedCrossRef

23.

Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3: 513–519.PubMed

24.

Kataoka A, Sadanaga N, Mimori K, Ueo H, Barnard GF, Sugimachi K, Auclair D, Chen LB, Mori M: Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis. Clin Cancer Res 2001, 7: 2815–2820.PubMed

25.

Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, Berkowitz RS: Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995, 218: 499–507. 10.1006/excr.1995.1184PubMedCrossRef

26.

Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW: Characterisation of human kallikrein 6/protease M expression in ovarian cancer.[erratum appears in Br J Cancer. 2005 Mar 14;92(5):983]. Br J Cancer 2004, 91: 725–731.PubMedCentralPubMed

27.

Sasaki H, Chen LB, Auclair D, Moriyama S, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y: Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis. Lung Cancer 2001, 34: 47–52. 10.1016/S0169-5002(01)00223-9PubMedCrossRef

28.

Zhao M, Begum S, Ha PK, Westra W, Califano J: Downregulation of RAD17 in head and neck cancer. Head Neck 2008, 30: 35–42. 10.1002/hed.20660PubMedCrossRef

Title: Differential hRad17 expression by histologic subtype of ovarian cancer
Authors: Jennifer L Young
E Colin Koon
Joseph Kwong
William R Welch
Michael G Muto
Ross S Berkowitz
Samuel C Mok
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2011
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-4-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Differential hRad17 expression by histologic subtype of ovarian cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil

Reinterpretation of evidence advanced for neo- oogenesis in mammals, in terms of a finite oocyte reserve

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

Luteal blood flow in patients undergoing GnRH agonist long protocol

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors